Medeon Biodesign, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was TWD 45.72 million compared to TWD 41.52 million a year ago. Net loss was TWD 193.73 million compared to TWD 124.64 million a year ago. Basic loss per share from continuing operations was TWD 2.11 compared to TWD 1.36 a year ago. Diluted loss per share from continuing operations was TWD 2.11 compared to TWD 1.36 a year ago.
For the nine months, sales was TWD 140.79 million compared to TWD 261.41 million a year ago. Net loss was TWD 1,000 million compared to TWD 249.21 million a year ago. Basic loss per share from continuing operations was TWD 10.87 compared to TWD 2.71 a year ago. Diluted loss per share from continuing operations was TWD 10.87 compared to TWD 2.71 a year ago.